Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
(Thomson Reuters ONE) -
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that it has entered into definitive
agreements to sell securities to certain accredited investors in a private
placement priced at-the-market, for aggregate gross proceeds of approximately
$3.7 million. The closing of the private placement is expected to occur on or
about September 13, 2017, subject to satisfaction of customary closing
conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the
offering.
Under the terms of the offering, Apricus will sell an aggregate of 2,136,614
shares of its common stock, at a price of $1.7275 per share. The purchasers will
also receive warrants to purchase up to an aggregate of 1,068,307 shares of
common stock at an exercise price of $1.67 per share which will expire 2.5 years
from the date of issuance.
Apricus intends to use the net proceeds from this offering for general corporate
purposes and working capital.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation
or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. The securities offered
and sold in the private placement have not been registered under the Securities
Act of 1933, as amended (the "Securities Act"), or any state securities laws,
and may not be offered or sold in the United States absent registration, or an
applicable exemption from registration under the Securities Act and applicable
state securities laws. Apricus has agreed to file one or more registration
statements with the SEC registering the resale by the purchasers of the Shares
and the shares issuable upon exercise of the Warrants.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus has two product
candidates currently in development. Vitaros is a product candidate in the
United States for the treatment of erectile dysfunction, which is in-licensed
from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan).
RayVa is our product candidate in Phase 2 development for the treatment of the
circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which
we own worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros((TM)) is Apricus' trademark in the United States, which is pending
registration and subject to the agreement with Allergan. Vitaros(®) is a
registered trademark of Ferring International Center S.A. in certain countries
outside of the United States. RayVa((TM)) is Apricus' trademark, which is
registered in certain countries throughout the world and pending registration in
the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act, as amended. Statements in this press
release that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other thing, statements regarding the
private placement, the expected gross proceeds, the expected use of proceeds and
the expected closing of the offering. Actual results could differ from those
projected in any forward-looking statements due to a variety of reasons that are
outside of Apricus' control, including, but not limited to: the satisfaction of
the closing conditions prior to the closing; Nasdaq may not approve the issuance
of the shares; additional costs as a result of the FDA review of the Vitaros new
drug application, including the fact that the FDA could require additional
clinical and pre-clinical data; Apricus' ability to have addressed any
conditions for approvability raised by the FDA in the 2008 action letter or the
FDA identifying other deficiencies in the resubmission; risks related to the
possibility of an advisory committee meeting related to Vitaros; the risks of
any additional adverse safety or other data arising from the sales and use of
Vitaros in certain countries in Europe and elsewhere; Apricus' financial
position and need for additional capital to fund its operations through the
FDA's review of the NDA, which may be adversely impacted if Apricus is unable to
maintain the continued listing of its common stock on the Nasdaq stock market;
competition in the ED market; and other risks identified by Apricus in its
reports filed with the Securities and Exchange Commission (SEC). These forward-
looking statements are made as of the date of this press release, and Apricus
assumes no obligation to update the forward-looking statements, or to update the
reasons why actual results could differ from those projected in the forward-
looking statements. Readers are urged to read the risk factors set forth in
Apricus' most recent annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q, and other filings made with the SEC. Copies of these reports
are available from the SEC's website at www.sec.gov or without charge from
Apricus.
CONTACT:
Matthew Beck
mbeck(at)troutgroup.com
The Trout Group
(646) 378-2933
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 11.09.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 559434
Anzahl Zeichen: 6653
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
